Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/17/2003EP1370562A1 Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
12/17/2003EP1370561A2 Tetrahydro-pyrazino[1,2-a]indoles for the treatment of central nervous disorders
12/17/2003EP1370560A1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
12/17/2003EP1370559A1 Triazolopyridines as anti-inflammatory agents
12/17/2003EP1370558A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
12/17/2003EP1370557A1 Benzimidazole anti-inflammatory compounds
12/17/2003EP1370556A1 Metalloproteinase inhibitors
12/17/2003EP1370554A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
12/17/2003EP1370553A2 Rho-kinase inhibitors
12/17/2003EP1370552A2 Rho-kinase inhibitors
12/17/2003EP1370551A2 New compounds useful as antibacterial agents
12/17/2003EP1370550A1 Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same
12/17/2003EP1370549A1 Methods for the preparation of mirtazapine intermediates
12/17/2003EP1370548A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same
12/17/2003EP1370547A1 Benzoaxathiepin derivatives and their use as medicines
12/17/2003EP1370546A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications
12/17/2003EP1370544A1 Nitric oxide donors based on metallic centres
12/17/2003EP1370543A2 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
12/17/2003EP1370542A1 Bicyclic guanidine derivatives and therapeutic uses thereof
12/17/2003EP1370540A1 Anti-thrombotic carboxylic acid amides, the production thereof and use of the same as medicaments
12/17/2003EP1370539A1 Hiv inhibiting n-aminoimidazole derivatives
12/17/2003EP1370538A1 Metalloproteinase inhibitors
12/17/2003EP1370537A1 Metalloproteinase inhibitors
12/17/2003EP1370536A1 Metalloproteinase inhibitors
12/17/2003EP1370535A1 Metalloproteinase inhibitors
12/17/2003EP1370534A1 Metalloproteinase inhibitors
12/17/2003EP1370533A2 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
12/17/2003EP1370531A1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
12/17/2003EP1370530A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
12/17/2003EP1370529A1 Substituted dimethyl- 1-(1-phenyl-cyclohexyl)-piperidin-3-yl methyl]-amines and the use of the same as analgesics
12/17/2003EP1370528A1 Mch antagonists and their use in the treatment of obesity
12/17/2003EP1370527A1 Indolone derivatives having vascular-damaging activity
12/17/2003EP1370526A1 Diamides which inhibit tryptase and factor xa activity
12/17/2003EP1370525A1 Biguanide derivatives
12/17/2003EP1370522A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
12/17/2003EP1370521A1 Formanilide derivatives as beta2-adrenoreceptor agonists
12/17/2003EP1370520A1 Aryl and biaryl compounds having mch modulatory activity
12/17/2003EP1370518A2 Tryptase-inhibitors
12/17/2003EP1370513A1 Malic acid addition salts of terbinafine
12/17/2003EP1370510A2 Hiv integrase inhibitors
12/17/2003EP1370302A1 Dry powder compositions comprising labelled particles for inhalation
12/17/2003EP1370298A1 Elongated and multiple spacers in activatible prodrugs
12/17/2003EP1370297A2 Method and composition
12/17/2003EP1370295A2 Neutral and anionic colloidal particles for gene delivery
12/17/2003EP1370294A2 Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
12/17/2003EP1370293A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
12/17/2003EP1370292A1 Use of cd23 antagonists for the treatment of neoplastic disorders
12/17/2003EP1370283A2 Prevention of recurrent viral disease
12/17/2003EP1370277A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
12/17/2003EP1370276A2 Medical uses of intercellular communication facilitating compounds
12/17/2003EP1370275A2 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
12/17/2003EP1370274A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases
12/17/2003EP1370273A1 Composition comprising cocoa and a dopamine d2 receptor agonist
12/17/2003EP1370271A2 A process for the manufacture of a herbal composition comprising a matrine
12/17/2003EP1370270A2 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
12/17/2003EP1370269A2 Pharmaceutical composition for the treatment of diabetes comprising, a 5-phenoxyalkal-2,4-thiazolidinedione derivative and a compound which stimulates insulin secretion
12/17/2003EP1370268A2 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
12/17/2003EP1370267A2 Use of propentofylline to control intraocular pressure
12/17/2003EP1370266A1 Method of treatment
12/17/2003EP1370265A1 Hiv inhibiting pyrazinone derivatives
12/17/2003EP1370264A2 Nicotinic receptor agonists for the treatment of inflammatory diseases
12/17/2003EP1370263A1 Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
12/17/2003EP1370262A1 New use of iloperidone
12/17/2003EP1370261A2 New use
12/17/2003EP1370260A2 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
12/17/2003EP1370259A1 Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
12/17/2003EP1370258A2 Peptide deformylase inhibitors
12/17/2003EP1370257A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
12/17/2003EP1370256A1 Novel inhibitors of formation of advanced glycation endproducts (ages)
12/17/2003EP1370255A2 Cdc25 phosphatase inhibitors
12/17/2003EP1370254A2 Copper chelators for treating ocular inflammation
12/17/2003EP1370253A2 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES
12/17/2003EP1370252A1 Thrombopoietin mimetics
12/17/2003EP1370251A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
12/17/2003EP1370250A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
12/17/2003EP1370249A1 Novel dendriticpolymers and their biomedical uses
12/17/2003EP1370247A2 Taste masked pharmaceutical compositions
12/17/2003EP1370246A2 Modulation of release from dry powder formulations
12/17/2003EP1370245A1 Method to prepare microparticles metoprolol that contain
12/17/2003EP1370244A1 Novel tablets and capsules and a process for its preparation
12/17/2003EP1370243A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
12/17/2003EP1370242A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
12/17/2003EP1370241A1 Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same
12/17/2003EP1370239A1 New composition
12/17/2003EP1370237A2 Presbyopia treatment by lens alteration
12/17/2003EP1370233A2 Filtering composition containing a 1,3,5-triazine derivative, a dibenzoylmethane derivative, and a 4,4-diarylbutadiene compound
12/17/2003EP1370228A2 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces
12/17/2003EP1370212A1 System and method for intranasal administration of lorazepam
12/17/2003EP1370211A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
12/17/2003EP1370210A2 Cholesterol-lowering agents as treatment for psychological and cognitive disorders
12/17/2003EP1370206A1 Devices for local and systemic delivery of active substances and methods of manufacturing thereof
12/17/2003EP1370158A1 Method and product for treating cancer in pets
12/17/2003EP1370152A2 Polybutene containing chewing gum and confection
12/17/2003EP1370150A1 One-step process for preparing chewing gum
12/17/2003EP1370148A1 Anticholesterolemic edible oil
12/17/2003EP1370144A1 Noninvasive measurements of chemical substances
12/17/2003EP1283845B1 Process for the preparation of pharmaceutically acceptable salts of (ss-rs)-s-adenosyl-l-methionine
12/17/2003EP1272470B1 Amorphous torasemide modification
12/17/2003EP1263425B1 Use of comt inhibitors as analgesics
12/17/2003EP1246825B1 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
1 ... 5241 5242 5243 5244 5245 5246 5247 5248 5249 5250 5251 5252 5253 5254 5255 5256 5257 5258 5259 5260 5261 ... 7860